ArticleTranslational cancer research2022
A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 9 citations in OpenAlex.
- Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Sleep at high altitude: A bibliometric study and visualization analysis from 1992 to 2022.Heliyon · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CD38 is a transmembrane glycoprotein that is relatively highly expressed on multiple myeloma (MM) cells, and CD38-targeting antibodies use pleiotropic mechanisms to kill MM cells. Immunotherapy, with an increased quality of response and acceptable toxicity, shows tremendous potential for treating MM. This research field study aimed to analyze all the relevant literature via bibliometrics to identify its course of development and structural relationships. Methods: A total of 1,030 relevant articles were retrieved from the Web of Science Core Collection (WoSCC) from 1985 to June 21, 2021. CiteSpace was employed to map authors/references/countries with nodes and links, extract highly cited keywords, analyze the time trends of keywords, recognize cocited authors/references, set timezone or timeline views, analyze burstness and generate a dual map. VOSviewer was used to recognize connections among journals and construct collaboration networks. bibliometric.com was utilized to trace advanced countries/regions in the research field. Results: All of the articles were cited 24,332 times in total, with an average of 23.62 times. Most articles were published in the United States of America (USA), far outweighing other countries/regions. The current hotspots in this field are related to the following keywords: "monoclonal antibody", "refractory MM", "idecabtagene vicleucel", and "B cell maturation antigen (BCMA)". Ten significant clusters, namely, "flow cytometry", "daratumumab", "BCMA", "cell line", "antitumor activity", "gene", "non-Hodgkin's lymphoma", "peripheral blood", "survival" and "anti-CD38", were extracted. The mechanism and effectiveness of CD38-targeting antibodies in treating MM have been studied. Future research hotspots will focus on new therapies for relapsed and refractory multiple myeloma (RRMM) patients. Conclusions: In the past, efforts were applied to elucidate the mechanism and effectiveness of CD38-targeting antibodies in treating MM. Future research hotspots will focus on anti-BCMA chimeric antigen receptor T cell (CAR-T) immunotherapy for patients with RRMM. According to this article, new researchers can discover its course of development and structural relationships in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.